InnoCare announces first patient dosed head-to-head in phase III head-to-head registration of mesotoclax with azicidin versus ventoclax with azicidin in naïve AML in China.
🇨🇳 China · Map
InnoCare announces first patient dosed head-to-head in phase III head-to-head registration of mesotoclax with azicidin versus ventoclax with azicidin in naïve AML in China.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in